Abstract
This study assessed response rates to combination dacarbazine (DTIC), BCNU (carmustine), cisplatin and tamoxifen (DBPT) chemotherapy in patients with progressive metastatic melanoma previously treated with DTIC, as an evaluation of DBPT as a second-line regimen, and as an indirect comparison of DBPT with DTIC. Thirty-five consecutive patients received DBPT. The patients were divided into two groups. Group 1 comprised 17 patients with progressive disease (PD) on DTIC + tamoxifen therapy who were switched directly to DBPT. Group 2 comprised 18 patients not immediately switched to DBPT and included patients who had either a partial response (PR; one patient) or developed stable disease (SD; four patients) with DTIC, or received adjuvant DTIC (nine patients). All except four patients had received tamoxifen at the time of initial DTIC treatment. Median times since stopping DTIC were 22 days (range 20–41) and 285 days (range 50–1240) in Groups 1 and 2 respectively. In Group 1, one patient developed SD for 5 months and the remainder had PD. In Group 2, there were two PRs, four patients with SD (4, 5, 6, and 6 months), and 11 with PD. These results indicate that the DBPT regimen is not of value in melanoma primarily refractory to DTIC. There were responses in patients not directly switched from DTIC to DBPT, suggesting combination therapy may be of value in a small subgroup of melanoma patients. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bajetta E, Buzzoni R and Vicario G (1995) Combined carboplatin and cytosine arabinoside in metastatic melanoma refractory to dacarbazine. Tumori 81: 238–240
Braybrooke J, Houlbrook S, Crawley JE, Propper DJ, O’Byrne K, Stratford IJ, Harris AL, Shuker DE and Talbot DC (2000) Evaluation of the alkaline comet assay and urine 3-methyl adenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen. Cancer Chemother Pharmacol 45: 111–119
Cree IA and Kurbacher CM (1997) Individualizing chemotherapy for solid tumors: is there any alternative?. Anti-Cancer Drugs 8: 541–548
Del Prete SA, Maurer LH, O’Donnell J, Forcier RJ and LeMarbre P (1984) Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treatment Reports 68: 1403–1405
Dorval T, Negrier S, Chevreau C, Avril MF, Baume D, Cupissol D, Oskam R, de Peuter R, Vinke J, Herrera A and Escudier B (1999) Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer 85: 1060–1066
Everall JD and Dowd PM (1979) Use of combination chemotherapy with CCNU, bleomycin, and vincristine in the treatment of metastatic melanoma in patients resistant to DTIC therapy. Cancer Treatment Reports 63: 151–155
Gehan A (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346–353
Hill GD, Krementz ET and Hill HZ (1984) Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 53: 1299–1305
Johnson DH, Presant C, Einhorn L, Bartolucci AA and Greco FA (1985) Cisplatin, vinblastine, and bleomycin in the treatment of metastatic melanoma: a phase II study of the Southeastern Cancer Study Group. Cancer Treatment Reports 69: 821–824
Johnston SR, Constenla DO, Moore J, Atkinson H, A’Hern RP, Dadian G, Riches PG and Gore ME (1998) Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 77: 1280–1286
Lee SM, Thatcher N and Margison GP (1991) O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res 51: 619–623
Margolin KA, Liu PY, Flaherty LE, Sosman JA, Walker MJ, Smith JW 3rd, Fletcher WS, Weiss GR, Unger JM and Sondak VK (1998) Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. J Clin Oncol 16: 664–669
Mastrangelo MJ, Bellet RE, Kane MJ and Berd D (1992) Chemotherapy of melanoma. Chemotherapy Source Book, Perry MC886–907, Williams and Wilkins: Baltimore
McClay EF and McClay ME (1994) Tamoxifen: is it useful in the treatment of patients with metastatic melanoma?. J Clin Oncol 12: 617–626
McClay EF and McClay ME (1996) Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 23: 744–753
McClay EF, Albright KD, Jones JA, Christen RD and Howell SB (1993 a) Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 53: 1571–1576
McClay EF, McClay ME, Albright KD, Jones JA, Christen RD, Alcaraz J and Howell SB (1993 b) Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation. Cancer 72: 1914–1918
Mulder NH, Sleijfer DT, de VE, Schraffordt KH and Willemse PH (1990) Phase II study of carboplatin and cytosine arabinoside in patients with disseminated malignant melanoma. J Cancer Res Clin Oncol 116: 301–302
Philip PA, Carmichael J, Tonkin K, Ganesan TA and Harris AL (1994) A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. Eur J Cancer 30: 1027–1029
Porcile G, Musso M, Boccardo F, Rosso R and Santi L (1979) Combination chemotherapy with vinblastine, bleomycin and methotrexate in DTIC-resistant metastatic melanoma. Tumori 65: 237–240
Propper D, Macaulay V, O’Byrne KJ, Braybrooke J, Wilner SM, Ganesan TS, Talbot DC and Harris AL (1998) A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 78: 1337–1341
Quagliana JM, Stephens RL, Baker LH and Costanzi JJ (1984) Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study. J Clin Oncol 2: 316–319
Reintgen D and Saba H (1993) Chemotherapy for stage 4 melanoma: a three-year experience with cisplatin, DTIC, BCNU, and tamoxifen. Semin Surg Oncol 9: 251–255
Rusciani L, Petraglia S, Alotto M, Calvieri S and Vezzoni G (1997) Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up. Cancer 79: 2354–2360
Saunders MP, Salisbury AJ, O’Byrne KJ, Souliotis VL, Varcoe SM, Talbot DC, Kyrtopoulos SA and Harris AL (1997) A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazine. Anticancer Res 17: 4677–4680
Saxman SB, Meyers ML, Chapman PP, Destro AN, Panageas KS, Begg CB, Monaco F, Agarwala SS, Schuchter LM, Ernstoff MS, Einhorn LH, Kirkwood JM and Houghton AN (1999) A phase III multicenter randomized trial of DTIC, cisplatin, BCNU and tamoxifen versus DTIC alone in patients with metastatic melanoma. Proc Annu Meet Am Soc Clin Oncol 18: 2068A
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Propper, D., Braybrooke, J., Levitt, N. et al. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. Br J Cancer 82, 1759–1763 (2000). https://doi.org/10.1054/bjoc.2000.1141
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1141